Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2015

View Archived Issues

KemPharm updates pipeline progress

Xenon initiates phase I trial of XEN-801 for acne

Resverlogix to explore apabetalone for complement-mediated diseases

Syros in-licenses tamibarotene and plans phase II trial in AML and MDS

CIRM grants USD 19.9 million to ImmunoCellular for the funding of ICT-107

Novo Nordisk discloses results from second phase IIIa trial of semaglutide in type 2 diabetes

Arrowhead reports phase II and preclinical results for siRNA therapies targeting HBV

AbbVie passes on Galapagos' filgotinib, plans to advance own JAK1 inhibitor to phase III

Fungal CYP51 inhibitors to overcome resistance

SNRI Effexor SR Capsules obtained approval in Japan

Microlin releases study results of anti-microRNA candidate in murine lung cancer model

EMA committee recommends approval of Numient for Parkinson's disease

FDA grants priority review to sBLA for nivolumab + ipilimumab regimen in untreated advanced melanoma

FDA gives fast track designation to OpRegen for dry AMD

Ocular Therapeutix submits NDA for Dextenza

GlaxoSmithKline's Zagallo receives approval in Japan

Interim results from a phase II study on oral Relugolix in prostate cancer patients

Shionogi's Mulpleta approved in Japan for thrombocytopenia

Verastem stops COMMAND study of VS-6063 in mesothelioma for futility

Columbia University in the City of New York patents MOR-1 agonists

Takeda Pharmaceutical reports development of acyl-CoA desaturase inhibitors

AbbVie Deutschland discloses 5-HT2C receptor agonists

Icahn School of Medicine at Mount Sinai describes PP2A activators

Eribulin sNDA for inoperable soft tissue sarcoma gets FDA grants priority review

FORUM Pharmaceuticals presents gamma-secretase modulators

Selumetinib plus HAART is effective in advanced HIV-associated Karposi's sarcoma

FDA accepts for filing Ontinua ER NDA

Tepotinib and gefitinib combination active in c-Met-positive EGFR mutant NSCLC asian patients

New results for epacadostat in combination with ipilimumab for the treatment of melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....